Serveur d'exploration sur l'Indium

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Scintigraphy and immunohistology of antimyosin-Fab during graft rejection.

Identifieur interne : 003B60 ( Main/Exploration ); précédent : 003B59; suivant : 003B61

Scintigraphy and immunohistology of antimyosin-Fab during graft rejection.

Auteurs : RBID : pubmed:10431996

English descriptors

Abstract

Up to now, the cellular localization pattern of monoclonal antimyosin antibodies (AMA) during acute rejection has not been described. Focused on this the authors made immunohistochemical and scintigraphic studies (AMS) with AMA in an animal transplantation model. Heterotopic cervical heart transplantation was performed in 12 mongrel dogs. Immunosuppression consisted of triple drug therapy. As standard the grafts were examined by daily transmural biopsies and routine histology. Dependent on the daily biopsy results, 0.5 mg of indium 111 ((111)In)-labeled AMA-Fab was injected. Subsequently every 2 hours transmural biopsy cylinders were taken out of the right ventricle and examined in indirect peroxidase staining technique. Forty-eight hours after AMA injection, scintigraphy in single photon emission computed tomography (SPECT) technique (AMS) was carried out and the heart-to-lung ratio (H/L-ratio) was calculated. The immunohistochemical maximum of AMA accumulation could be found 20 to 72 hours after AMA injection. This means that a scintigraphic examination should be done earlier than 20 hours and later than 3 days after injection. Dependent on the grades of bioptic rejection diagnosis a specific morphologic AMA localization was seen (grade I+II intercellular and slightly intracellular detection of AMA, grade III strongly intracellular and in particular perinuclear accumulation of the antibody, p<0.01). Moreover, the authors found a good correlation between scintigraphic H/L-ratio results and the corresponding histologic findings (grade I: H/L = 2.1 +/- 0.2; grade II: H/L = 3.1 +/- 0.2; grade III: H/L = 3.5 +/- 0.3; n = 19; p<0.02). The recently described positive AMS scans even in cases of mild rejection seem to be subject to an intercellular AMA localization. This typical AMA morphology during mild rejection favors the theory of the pore-forming protein allowing the efflux of myosin fragments as effector mechanism of cytotoxic lymphocytes in the early phase of acute rejection. The immunohistochemical AMA examination could explain the present discrepancy between positive AMS results of an intracellular protein in cases of mild or moderate acute rejection when visible cellular damage in the corresponding routine histology is absent.

PubMed: 10431996

Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Scintigraphy and immunohistology of antimyosin-Fab during graft rejection.</title>
<author>
<name sortKey="Breuer, M" uniqKey="Breuer M">M Breuer</name>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Cardiovascular Surgery, Klinikum Bogenhausen, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Cardiovascular Surgery, Klinikum Bogenhausen, Munich</wicri:regionArea>
<placeName>
<region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Sch Tz, A" uniqKey="Sch Tz A">A Schütz</name>
</author>
<author>
<name sortKey="Engelhardt, M" uniqKey="Engelhardt M">M Engelhardt</name>
</author>
<author>
<name sortKey="Hammer, C" uniqKey="Hammer C">C Hammer</name>
</author>
<author>
<name sortKey="Kemkes, B M" uniqKey="Kemkes B">B M Kemkes</name>
</author>
</titleStmt>
<publicationStmt>
<date when="1999">1999</date>
<idno type="RBID">pubmed:10431996</idno>
<idno type="pmid">10431996</idno>
<idno type="wicri:Area/Main/Corpus">003E40</idno>
<idno type="wicri:Area/Main/Curation">003E40</idno>
<idno type="wicri:Area/Main/Exploration">003B60</idno>
</publicationStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Antibodies, Monoclonal (diagnostic use)</term>
<term>Biopsy</term>
<term>Disease Models, Animal</term>
<term>Dogs</term>
<term>Extracellular Space (immunology)</term>
<term>Graft Rejection (immunology)</term>
<term>Graft Rejection (pathology)</term>
<term>Graft Rejection (radionuclide imaging)</term>
<term>Heart Transplantation (immunology)</term>
<term>Heart Transplantation (pathology)</term>
<term>Heart Transplantation (radionuclide imaging)</term>
<term>Immunoenzyme Techniques</term>
<term>Immunoglobulin Fab Fragments (diagnostic use)</term>
<term>Immunosuppressive Agents (therapeutic use)</term>
<term>Indium Radioisotopes (diagnostic use)</term>
<term>Intracellular Fluid (immunology)</term>
<term>Lung (radionuclide imaging)</term>
<term>Myosins (analysis)</term>
<term>Neck</term>
<term>Radioimmunodetection</term>
<term>Radiopharmaceuticals (diagnostic use)</term>
<term>T-Lymphocytes, Cytotoxic (immunology)</term>
<term>T-Lymphocytes, Cytotoxic (pathology)</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
<term>Transplantation, Heterotopic (immunology)</term>
<term>Transplantation, Heterotopic (pathology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en">
<term>Myosins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en">
<term>Antibodies, Monoclonal</term>
<term>Immunoglobulin Fab Fragments</term>
<term>Indium Radioisotopes</term>
<term>Radiopharmaceuticals</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Extracellular Space</term>
<term>Graft Rejection</term>
<term>Heart Transplantation</term>
<term>Intracellular Fluid</term>
<term>T-Lymphocytes, Cytotoxic</term>
<term>Transplantation, Heterotopic</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Graft Rejection</term>
<term>Heart Transplantation</term>
<term>T-Lymphocytes, Cytotoxic</term>
<term>Transplantation, Heterotopic</term>
</keywords>
<keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en">
<term>Graft Rejection</term>
<term>Heart Transplantation</term>
<term>Lung</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Immunosuppressive Agents</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Biopsy</term>
<term>Disease Models, Animal</term>
<term>Dogs</term>
<term>Immunoenzyme Techniques</term>
<term>Neck</term>
<term>Radioimmunodetection</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Up to now, the cellular localization pattern of monoclonal antimyosin antibodies (AMA) during acute rejection has not been described. Focused on this the authors made immunohistochemical and scintigraphic studies (AMS) with AMA in an animal transplantation model. Heterotopic cervical heart transplantation was performed in 12 mongrel dogs. Immunosuppression consisted of triple drug therapy. As standard the grafts were examined by daily transmural biopsies and routine histology. Dependent on the daily biopsy results, 0.5 mg of indium 111 ((111)In)-labeled AMA-Fab was injected. Subsequently every 2 hours transmural biopsy cylinders were taken out of the right ventricle and examined in indirect peroxidase staining technique. Forty-eight hours after AMA injection, scintigraphy in single photon emission computed tomography (SPECT) technique (AMS) was carried out and the heart-to-lung ratio (H/L-ratio) was calculated. The immunohistochemical maximum of AMA accumulation could be found 20 to 72 hours after AMA injection. This means that a scintigraphic examination should be done earlier than 20 hours and later than 3 days after injection. Dependent on the grades of bioptic rejection diagnosis a specific morphologic AMA localization was seen (grade I+II intercellular and slightly intracellular detection of AMA, grade III strongly intracellular and in particular perinuclear accumulation of the antibody, p<0.01). Moreover, the authors found a good correlation between scintigraphic H/L-ratio results and the corresponding histologic findings (grade I: H/L = 2.1 +/- 0.2; grade II: H/L = 3.1 +/- 0.2; grade III: H/L = 3.5 +/- 0.3; n = 19; p<0.02). The recently described positive AMS scans even in cases of mild rejection seem to be subject to an intercellular AMA localization. This typical AMA morphology during mild rejection favors the theory of the pore-forming protein allowing the efflux of myosin fragments as effector mechanism of cytotoxic lymphocytes in the early phase of acute rejection. The immunohistochemical AMA examination could explain the present discrepancy between positive AMS results of an intracellular protein in cases of mild or moderate acute rejection when visible cellular damage in the corresponding routine histology is absent.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">10431996</PMID>
<DateCreated>
<Year>1999</Year>
<Month>08</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>08</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2009</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0003-3197</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>50</Volume>
<Issue>7</Issue>
<PubDate>
<Year>1999</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Angiology</Title>
<ISOAbbreviation>Angiology</ISOAbbreviation>
</Journal>
<ArticleTitle>Scintigraphy and immunohistology of antimyosin-Fab during graft rejection.</ArticleTitle>
<Pagination>
<MedlinePgn>563-71</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Up to now, the cellular localization pattern of monoclonal antimyosin antibodies (AMA) during acute rejection has not been described. Focused on this the authors made immunohistochemical and scintigraphic studies (AMS) with AMA in an animal transplantation model. Heterotopic cervical heart transplantation was performed in 12 mongrel dogs. Immunosuppression consisted of triple drug therapy. As standard the grafts were examined by daily transmural biopsies and routine histology. Dependent on the daily biopsy results, 0.5 mg of indium 111 ((111)In)-labeled AMA-Fab was injected. Subsequently every 2 hours transmural biopsy cylinders were taken out of the right ventricle and examined in indirect peroxidase staining technique. Forty-eight hours after AMA injection, scintigraphy in single photon emission computed tomography (SPECT) technique (AMS) was carried out and the heart-to-lung ratio (H/L-ratio) was calculated. The immunohistochemical maximum of AMA accumulation could be found 20 to 72 hours after AMA injection. This means that a scintigraphic examination should be done earlier than 20 hours and later than 3 days after injection. Dependent on the grades of bioptic rejection diagnosis a specific morphologic AMA localization was seen (grade I+II intercellular and slightly intracellular detection of AMA, grade III strongly intracellular and in particular perinuclear accumulation of the antibody, p<0.01). Moreover, the authors found a good correlation between scintigraphic H/L-ratio results and the corresponding histologic findings (grade I: H/L = 2.1 +/- 0.2; grade II: H/L = 3.1 +/- 0.2; grade III: H/L = 3.5 +/- 0.3; n = 19; p<0.02). The recently described positive AMS scans even in cases of mild rejection seem to be subject to an intercellular AMA localization. This typical AMA morphology during mild rejection favors the theory of the pore-forming protein allowing the efflux of myosin fragments as effector mechanism of cytotoxic lymphocytes in the early phase of acute rejection. The immunohistochemical AMA examination could explain the present discrepancy between positive AMS results of an intracellular protein in cases of mild or moderate acute rejection when visible cellular damage in the corresponding routine histology is absent.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Breuer</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<Affiliation>Department of Cardiovascular Surgery, Klinikum Bogenhausen, Munich, Germany.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Schütz</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Engelhardt</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hammer</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kemkes</LastName>
<ForeName>B M</ForeName>
<Initials>BM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Angiology</MedlineTA>
<NlmUniqueID>0203706</NlmUniqueID>
<ISSNLinking>0003-3197</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Immunoglobulin Fab Fragments</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Indium Radioisotopes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Radiopharmaceuticals</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.4.1</RegistryNumber>
<NameOfSubstance>Myosins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName MajorTopicYN="N">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Biopsy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Extracellular Space</DescriptorName>
<QualifierName MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Graft Rejection</DescriptorName>
<QualifierName MajorTopicYN="Y">immunology</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Heart Transplantation</DescriptorName>
<QualifierName MajorTopicYN="Y">immunology</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Immunoglobulin Fab Fragments</DescriptorName>
<QualifierName MajorTopicYN="N">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName>
<QualifierName MajorTopicYN="N">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Intracellular Fluid</DescriptorName>
<QualifierName MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lung</DescriptorName>
<QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myosins</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neck</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radioimmunodetection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName>
<QualifierName MajorTopicYN="N">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
<QualifierName MajorTopicYN="N">immunology</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Transplantation, Heterotopic</DescriptorName>
<QualifierName MajorTopicYN="Y">immunology</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>1999</Year>
<Month>8</Month>
<Day>4</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>1999</Year>
<Month>8</Month>
<Day>4</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>1999</Year>
<Month>8</Month>
<Day>4</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">10431996</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B60 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B60 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=   *** parameter Area/wikiCode missing *** 
   |area=    IndiumV2
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:10431996
   |texte=   Scintigraphy and immunohistology of antimyosin-Fab during graft rejection.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:10431996" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a IndiumV2 

Wicri

This area was generated with Dilib version V0.5.76.
Data generation: Tue May 20 07:24:43 2014. Site generation: Thu Mar 7 11:12:53 2024